Aktienanalyse zu vTv Therapeutics Inc (VTVT)VTVTvTv Therapeutics Inc

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

vTv Therapeutics Inc is currently not a strong buy due to recent earnings misses and a low RSI of 40.52, indicating potential weakness. However, the stock has shown significant growth over the past year with a 75.87% increase, and analysts maintain a buy rating with targets suggesting a potential upside of 30% to 107% from the current price of $32.36. The main risk is the recent earnings miss, reporting a Q2 EPS of -1.05 against an expectation of -0.75, which raises concerns about future profitability.

4 analysts cover VTVT: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 51.33.